| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/09/2014 | CN102357194B Traditional Chinese medicine composition for preventing and treating lung injury due to radioactive radon and daughters thereof |
| 04/09/2014 | CN102335160B Photosensitive medicament patch and preparation method thereof |
| 04/09/2014 | CN102329327B Furan derivatives and preparation method and application thereof |
| 04/09/2014 | CN102309656B Traditional Chinese medicine composition with effect of preventing and treating cancers and medicinal application of traditional Chinese medicine composition |
| 04/09/2014 | CN102285948B 4-hydroxy-benzopyranone derivates and application thereof |
| 04/09/2014 | CN102219812B Tumor targeting deoxyglucose composite drug and preparation method thereof |
| 04/09/2014 | CN102206281B Fusion protein TETPH, expression vector and construction method thereof |
| 04/09/2014 | CN102046657B Antibodies directed to angiopoietin-1 and angiopoietin-2 and use thereof |
| 04/09/2014 | CN102026961B 酰胺化合物 Amide compounds |
| 04/09/2014 | CN101935336B Method for preparing water-soluble taxane medicament and application thereof |
| 04/09/2014 | CN101897705B Compound having function of resisting tumor activity |
| 04/09/2014 | CN101875682B Ginsengenin 20 (R)-methoxy-dammarane-3 beta, 12 beta, 25-triol and preparation method and medical use thereof |
| 04/09/2014 | CN101824082B N-end deletion type p43 protein and application thereof in medicaments for treating tumors |
| 04/09/2014 | CN101721417B Entogastric lingering floating slow-release tablet for treating malignant tumor of gastrointestinal tract |
| 04/09/2014 | CN101663283B Quinoxaline compounds and use thereof |
| 04/09/2014 | CN101511870B Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor |
| 04/08/2014 | US8691982 Pyrazolo[1,5-a]-1,3,5-triazine derivatives, preparation thereof, and therapeutic use thereof |
| 04/08/2014 | US8691981 Crystalline forms of (S)-1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide |
| 04/08/2014 | US8691848 Inhibitors of caspases |
| 04/08/2014 | US8691838 Heterocycles as protein kinase inhibitors |
| 04/08/2014 | US8691829 Treatment of liver disorders with PI3K inhibitors |
| 04/08/2014 | US8691828 Thienopyrimidine as CDC7 kinase inhibitors |
| 04/08/2014 | US8691822 Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof |
| 04/08/2014 | US8691820 CDK inhibitors |
| 04/08/2014 | US8691814 Deazapurines and uses thereof |
| 04/08/2014 | US8691810 Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases |
| 04/08/2014 | US8691809 Substituted benzoazepines as toll-like receptor modulators |
| 04/08/2014 | US8691799 Materials and methods for treatment of cancer and identification of anti-cancer compounds |
| 04/08/2014 | US8691785 Compositions and methods for non-parenteral delivery of oligonucleotides |
| 04/08/2014 | US8691764 Inhibitors of NF-κB activity |
| 04/08/2014 | US8691749 Peptide and use thereof |
| 04/08/2014 | US8691507 Inhibitors of human EZH2 and methods of use thereof |
| 04/08/2014 | US8691503 Method and nucleic acids for the analysis of colorectal cell proliferative disorders |
| 04/08/2014 | US8691231 Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| 04/08/2014 | US8691209 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| 04/08/2014 | US8691206 Formation of hydrogel in the presence of peroxidase and low concentration of hydrogen peroxide |
| 04/08/2014 | US8691184 Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same |
| 04/08/2014 | CA2711532C Agent for prevention of alcoholic hepatopathy |
| 04/08/2014 | CA2673483C Compositions of chk1 inhibitors |
| 04/08/2014 | CA2641933C Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors |
| 04/08/2014 | CA2641776C Pyrazoloquinolones are potent parp inhibitors |
| 04/08/2014 | CA2634553C Triazole derivatives |
| 04/08/2014 | CA2630271C Fused bicyclic mtor inhibitors |
| 04/08/2014 | CA2621443C Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors |
| 04/08/2014 | CA2598216C Androgen receptor modulator compounds and methods |
| 04/08/2014 | CA2593523C Treatment of drug-resistant proliferative disorders |
| 04/08/2014 | CA2580811C Carbostyril compound |
| 04/08/2014 | CA2572047C Octahydropyrrolo[2,3,c]pyridine derivatives and pharmaceutical use thereof |
| 04/08/2014 | CA2506310C New antagonist derivatives for the vitronectin receptor, their preparation method, their application as medication and the pharmaceutical compositions containing them |
| 04/08/2014 | CA2378402C Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
| 04/03/2014 | WO2014052831A1 Anti-migration and anti-invasion thiazole analogs for treatment of cellular proliferative disease |
| 04/03/2014 | WO2014052828A1 Compositions and methods for modulating tlr4 |
| 04/03/2014 | WO2014052699A1 Azaquinazoline inhibitors of atypical protein kinase c |
| 04/03/2014 | WO2014052669A1 Modulation of ire1 |
| 04/03/2014 | WO2014052550A1 Use of parp inhibitors to treat breast cancer |
| 04/03/2014 | WO2014052471A1 Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer |
| 04/03/2014 | WO2014052237A1 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| 04/03/2014 | WO2014052064A1 Mesothelin antibodies and methods for eliciting potent antitumor activity |
| 04/03/2014 | WO2014051519A1 Telomerase inhibitors for use in therapy |
| 04/03/2014 | WO2014051412A1 Anti alpha-gal igm monoclonal antibody capable of recognising cells infected with the human papillomavirus, and method for obtaining same |
| 04/03/2014 | WO2014051359A1 Pharmaceutical composition comprising neferine as active ingredient for preventing or treating hepatoma |
| 04/03/2014 | WO2014051056A1 Crystals of glycine derivative and pharmaceutical use thereof |
| 04/03/2014 | WO2014051022A1 Fgfr3 fusion gene and pharmaceutical drug targeting same |
| 04/03/2014 | WO2014050912A1 Liquid medicine having carbon dioxide dissolved therein, and therapeutic method using same |
| 04/03/2014 | WO2014050781A1 Ret inhibitor |
| 04/03/2014 | WO2014050779A1 Combination of gsk3 inhibitor and anti-dr5 antibody |
| 04/03/2014 | WO2014050509A1 Liposome and liposome preparation |
| 04/03/2014 | WO2014049619A1 Cancer chemotherapeutic agent/formulation, manufacture and use thereof |
| 04/03/2014 | WO2014049578A1 New anti-invasive compounds |
| 04/03/2014 | WO2014049364A1 Indole derivatives |
| 04/03/2014 | WO2014049100A1 Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents |
| 04/03/2014 | WO2014049099A1 Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents |
| 04/03/2014 | WO2014049071A1 Modulators of androgen synthesis |
| 04/03/2014 | WO2014048998A1 5-fluoruoracil derivatives |
| 04/03/2014 | WO2014048945A1 Bet protein-inhibiting 5-aryl triazole azepines |
| 04/03/2014 | WO2014048939A1 Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| 04/03/2014 | WO2014048921A1 Combinations and uses thereof |
| 04/03/2014 | WO2014048894A1 Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders |
| 04/03/2014 | WO2014048881A1 Combination of regorafenib and acetylsalicylic acid for treating cancer |
| 04/03/2014 | WO2014048878A1 Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia |
| 04/03/2014 | WO2014048869A1 Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases |
| 04/03/2014 | WO2014048568A1 Radiopharmaceutical products for diagnosis and therapy of adrenal carcinoma |
| 04/03/2014 | WO2014048532A1 Quinazolinone derivatives as parp inhibitors |
| 04/03/2014 | WO2014048480A1 Organogold complexes for use in treating cancer |
| 04/03/2014 | WO2014048379A1 Drug composition for treating tumors and application thereof |
| 04/03/2014 | WO2014048377A1 Drug composition for treating tumors and application thereof |
| 04/03/2014 | WO2014048313A1 Condensation product of theanine derivative and carboxylic acid coumarin derivative, intermediate of the condensation product, method for preparing same, and use thereof |
| 04/03/2014 | WO2014048109A1 Reagent for targeting degradation of bcr-abl protein and use in preparation of philadelphia chromosome-positive tumor-curing medicine |
| 04/03/2014 | WO2014048071A1 Method and pharmaceutical composition for inhibiting pi3k/akt/mtor signal path |
| 04/03/2014 | WO2014048065A1 Triazolyl derivatives as syk inhibitors |
| 04/03/2014 | WO2014048060A1 Anti-inflammatory drug against cancer and aids with radiotherapy and preparation method thereof |
| 04/03/2014 | WO2014048033A1 Polymorphs of cddo ethyl ester and uses thereof |
| 04/03/2014 | WO2014047973A1 Monoclonal antibodies specifically recognizing b-raf mutant proteins and preparation method and use thereof |
| 04/03/2014 | WO2014047783A1 Pharmaceutical composition containing triptolide and triptolide derivative and bcl-2 inhibitor and use thereof |
| 04/03/2014 | WO2014047782A1 Pharmaceutical composition containing resveratrol and resveratrol derivative and bcl-2 inhibitor and use thereof |
| 04/03/2014 | WO2014047780A1 Pharmaceutical composition containing apigenin and apigenin derivative and oridonin and oridonin derivative and use thereof |
| 04/03/2014 | WO2014047779A1 Pharmaceutical composition containing evodiamine and evodiamine derivative and bcl-2 inhibitor and use thereof |
| 04/03/2014 | WO2014025199A3 Staphylococcal enterotoxin-derived superantigen mutant, fusion protein in which target-specific polypeptides are connected to the mutant and use thereof |
| 04/03/2014 | WO2014025198A3 Lfa3 mutant, fusion protein in which target-specific polypeptides are connected to the mutant or lfa3 cd2 binding region, and use thereof |
| 04/03/2014 | WO2014024077A9 5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS |